Advertisement
Canada markets open in 42 minutes

  • S&P/TSX

    22,011.72
    +139.76 (+0.64%)
     

  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     

  • DOW

    38,503.69
    +263.71 (+0.69%)
     

  • CAD/USD

    0.7293
    -0.0028 (-0.38%)
     

  • CRUDE OIL

    82.93
    -0.43 (-0.52%)
     

  • Bitcoin CAD

    91,148.01
    +750.19 (+0.83%)
     

  • CMC Crypto 200

    1,439.42
    +15.32 (+1.08%)
     

  • GOLD FUTURES

    2,331.60
    -10.50 (-0.45%)
     

  • RUSSELL 2000

    2,002.64
    +35.17 (+1.79%)
     

  • 10-Yr Bond

    4.6420
    +0.0440 (+0.96%)
     

  • NASDAQ futures

    17,733.75
    +127.00 (+0.72%)
     

  • VOLATILITY

    15.70
    +0.01 (+0.06%)
     

  • FTSE

    8,087.46
    +42.65 (+0.53%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • CAD/EUR

    0.6826
    -0.0010 (-0.15%)
     
MARKETS LIVE BLOG:

NASDAQ FUTURES POP, TESLA STOCK SURGES AFTER EARNINGS

Tesla shares jump after EV maker vows to speed up launch of more affordable models

HTG Molecular Diagnostics to Announce Second Quarter 2021 Financial Results and Host Conference Call on Thursday, August 12

HTG Molecular Diagnostics, Inc.
·1 min read

TUCSON, Ariz., Aug. 03, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM), a life science company whose mission is to advance precision medicine, today announced that it will report its financial results for the second quarter ended June 30, 2021 after the market close on Thursday, August 12, 2021. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 4:30 pm ET.

Conference Call & Webcast Details

Date:

Thursday, August 12

Time:

4:30 pm ET

Toll Free:

877-407-0789

International:

201-689-8562

Conference ID:

13721188

Webcast:

http://public.viavid.com/index.php?id=145556

About HTG
HTG is focused on NGS-based molecular profiling. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. Its mission is to empower precision medicine.

Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
Phone: (617) 430-7577
Email: arr@lifesciadvisors.com